Lidaprim (Sulfametrole, Trimethoprim)

The sulfametrole component blocks dihydropteroate synthase, preventing the first step of bacterial folic‑acid synthesis. Trimethoprim inhibits dihydrofolate reductase, the second step. By halting both stages, the combination stops production of tetrahydrofolate, a molecule essential for bacterial DNA, RNA and protein synthesis, resulting in a bacteriostatic effect.

The dosage of Lidaprim is determined by the prescribing healthcare professional based on the specific infection, patient age, weight, renal function and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Lidaprim in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To request Lidaprim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lidaprim offers a dual‑mechanism approach by combining a sulfonamide with trimethoprim, which can provide broader coverage against certain Gram‑negative and Gram‑positive bacteria compared with single‑agent sulfonamides or trimethoprim alone. Choice of therapy depends on local resistance patterns, patient tolerance and specific infection type.

Lidaprim tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Lidaprim is taken orally, usually with a full glass of water. It may be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals to optimize absorption and minimize gastrointestinal upset.

Serious adverse reactions, though rare, include severe skin reactions such as Stevens‑Johnson syndrome, blood dyscrasias like agranulocytosis, hepatic failure, and significant hypersensitivity reactions. Patients should seek immediate medical attention if they develop rash, fever, jaundice, or signs of infection.

Lidaprim is contraindicated in individuals with a known hypersensitivity to sulfonamides, trimethoprim, or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless dose adjustments are made, and in those with certain blood disorders where folate antagonism could worsen the condition.